Unexpectedly rumored cold power against Kofid

Posted in Infectious Diseases Magazine Earlier this month, the study analyzed data from the country’s human science and responding to the SARS-COV-2 (Heros) study, which tracked more than 4,100 people in 1,394 families from May 2020 to February 2021.

The researchers found that people, especially children with the last nose virus infection, were less likely to develop SARS-COV-2 in the following weeks. This effect is believed to be linked to antiviral defenses. Nasal viruses lead to a strong response to the viruses in the airways, which can temporarily aim to the immune system to fight other viruses.

The author of the study in the National Jewish study said: “The results we found indicate that the immunity boost from the last cold may give the authority an early advantage in fighting SARS-COV-2 before it has an opportunity to enjoy.” “This may help explain the reason for children who tend to get more colds more than adults, in general, to the exposure of long and less severe cases.”

Using thousands of self-collected nasal swabs, the team tested both SARS-COV-2 and other joint respiratory viruses, including nose viruses, in participants of all ages. They also analyzed the genetic expression of the airway to know the impact of modern viral infections on the antiviral defenses of the body. Children have a higher essential expression of genes associated with viruses-proteins that act as the first line of the immune system against viruses-compared to adults.

Although this phenomenon, known as heterogeneous viral overlap, is observed with other respiratory viruses, this is the first future study showing that it may also occur with SARS-COV-2.

“This does not mean that people should intentionally try to have a cold,” said Cameel Moore, the doctorate and the main author of the study in national national health. “But understanding how a virus can affect the body’s response to another can help us develop new prevention strategies, especially for the weak population.”

The research depends on the previous results of the Heros study, which shows that children are six times less likely than adults to develop COVID symptoms. The new data highlights the role that each of the immune differences associated with age and the last viral exposure in that protection may play.

Researchers in national Jewish health conducted the study in cooperation with partners from 12 cities across the United States.